Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Medincell S A manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This total dispersion suggests that the company's current patent activity, though small in volume, covers different technical niches within the biotechnology field. The 2 pending office actions are being reviewed independently by different groups at the USPTO.
KWON, JOHN SEUNGJAI is the busiest examiner, currently responsible for 1 pending office action. With 2 distinct examiners and 2 distinct art units involved, there is no overlap in the prosecution of the 2 pending office actions. This requires the company to manage two separate sets of examination standards and examiner preferences. Practitioners should be prepared to address the specific requirements of each of the 2 distinct art units to successfully navigate the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
| PEEBLES, KATHERINE | 1 | 35.6% | +48.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283350 | Pharmaceutical Composition | KWON, JOHN SEUNGJAI | — |
| 18267637 | PHARMACEUTICAL COMPOSITION | PEEBLES, KATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283350 | Pharmaceutical Composition | KWON, JOHN SEUNGJAI | 1615 | §103 | Final Rejection | — | Pending | Sep 21, 2023 |
| 18267637 | PHARMACEUTICAL COMPOSITION | PEEBLES, KATHERINE | 1617 | §103Other | Final Rejection | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedincell S A has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
John Seungjai Kwon has the most, with 1 of Medincell S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.